Leica Microsystems acquires Genetix to strengthen life science imaging portfolio
25 March 2010
Leica Microsystems has acquired UK company Genetix Ltd, a provider of systems for imaging and image analysis for clinical research.
This acquisition brings together Genetix’ expertise in developing and marketing imaging systems and software for clinical and research applications, with Leica Microsystems’ microscopes and other life science instrumentation.
The merger will enable both companies to fully realize their potential through the combination of their ideally complemented skill sets.
Genetix will exist as a separate business unit within Leica Microsystems and Genetix products will continue to be marketed and sold through existing channels. Customer services such as product ordering, applications support and instrument service for Genetix products will remain unchanged.
Charles de Rohan, Head of Genetix Business Unit within Leica Microsystems, said: “Joining together with Leica Microsystems gives Genetix greater access to global markets and increased financial resources to achieve its growth plans. Over the past decade Genetix has been building its presence in the life sciences, diagnostics and digital pathology segments through a combination of internal product development and acquisitions.
"Combining our strengthening presence with Leica Microsystems’ R&D capabilities, greater resources and global reach is in the best interests of our shareholders, customers and employees and will maximize the potential of our innovative technology. I would like to take this opportunity to thank all our customers for their continued support."
Stefan Traeger, Managing Director Life Science Division, Leica Microsystems, said: "Genetix’ extensive expertise will be invaluable for us. Their software capabilities, specifically in analytical software, will help us to make progress in the area of virtual microscopy, which is a field we have only recently stepped into. In addition, Genetix’ experience and market leading products in cell biology and genetics will expand our reach into the drug discovery and development markets.”